FDA Perspectives on Biosimilar BLA-Manufacturing (28of33) Quality – Oct. 16-17, 2019

FDA Perspectives on Biosimilar BLA-Manufacturing (28of33) Quality – Oct. 16-17, 2019
Share:

Download MP3


Similar Tracks

Data Quality Expectations for Biosimilars with Case Studies (29of33) Quality – Oct. 16-17, 2019 U.S. Food and Drug Administration
PFDD Workshop to Discuss Methodologic & Other Challenges Related to Patient Experience Data – Part 1 U.S. Food and Drug Administration
Increasing the Efficiency of Biosimilar Development Programs (Day 1) U.S. Food and Drug Administration
FDA Webinar on Allergen Labeling for Retail Food Stores and Food Service Establishments U.S. Food and Drug Administration
Clinicians Connect: Conversations w/ FDA's CMO on reducing cases of congenital syphilis & syphilis U.S. Food and Drug Administration
PFDD Workshop to Discuss Methodologic & Other Challenges Related to Patient Experience Data – Part 2 U.S. Food and Drug Administration
PFDD Workshop to Discuss Methodologic & Other Challenges Related to Patient Experience Data – Part 3 U.S. Food and Drug Administration
The Basics of Biosimilars U.S. Food and Drug Administration
The Biosimilar Development Process U.S. Food and Drug Administration
Biosimilars: Manufacturing and Inherent Variation U.S. Food and Drug Administration
FDA FY2025 Small Business Fair U.S. Food and Drug Administration
Increasing the Efficiency of Biosimilar Development Programs (Day 2) U.S. Food and Drug Administration
How Biomarkers Can Improve the Drug Development Process U.S. Food and Drug Administration
Data Requirements for Biosimilars U.S. Food and Drug Administration
Biosimilars: Critical Quality Attributes U.S. Food and Drug Administration
MEDIA CALL: FDA’s Final Rule on "Healthy" Claim – 12/19/2024 U.S. Food and Drug Administration
Ovarian Cancer: Moving to a Personalized Treatment Approach U.S. Food and Drug Administration
National Drug Code (NDC) for Healthcare Providers U.S. Food and Drug Administration
Biosimilars: Approval Process U.S. Food and Drug Administration
FDA Review and Approval Process for Biosimilar Medications U.S. Food and Drug Administration